After US FDA Advisors Unanimously Back First OTC Naloxone Proposal, Meeting On Second Not Needed
Executive Summary
“Meeting is no longer needed,” agency states in announcement. The same committees’ unanimous recommendation during a meeting in February on Emergent’s sNDA for OTC sales of 4-mg naloxone nasal spray made a repeat for HRT’s NDA for 3-mg spray unnecessary.
You may also be interested in...
HRT Prioritizes Access To Affordable Naloxone As US FDA Approves Second OTC Formulation
Co-founder and CEO Michael Hufford says HRT hopes to distribute first commercial supply in early 2024. Firm is engaging additional funding partners to help make its affordable opioid overdose treatment more accessible.
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.
Hitting A Moving Target: Teva’s Dethlefs Discusses US Complex Generics
With a number of US complex generic opportunities in Teva’s pipeline, the company’s executive vice president for North America commercial, Sven Dethlefs, talks to Generics Bulletin about the challenges of bringing complex products to market against a backdrop of evolving FDA requirements.